Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
June 27, 2024 08:00 ET
|
Rezolute, Inc.
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
June 24, 2024 08:00 ET
|
Rezolute, Inc.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
June 13, 2024 23:30 ET
|
Rezolute, Inc.
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024 16:01 ET
|
Rezolute, Inc.
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Rezolute to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 08:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel,...
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
May 21, 2024 16:05 ET
|
Rezolute, Inc.
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease...
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
May 15, 2024 16:05 ET
|
Rezolute, Inc.
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology...
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
April 23, 2024 08:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel,...
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
March 06, 2024 07:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel,...
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
February 13, 2024 16:05 ET
|
Rezolute, Inc.
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for...